An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Aldeyra Therapeutics, Inc. (ALDX) will host a conference call on March 9, 2023, at 8:00 a.m. ET to discuss its financial results for the year ended December 31, 2022, and recent corporate highlights. The call is accessible to both domestic and international callers with dedicated dial-in numbers. Investors can also access a live audio webcast of the conference through Aldeyra’s website, where the event will remain archived for 90 days. Aldeyra is a clinical-stage biotechnology company focused on therapies for immune-mediated diseases, with key product candidates under FDA review.
Positive
Upcoming conference call on financial results and corporate highlights could boost investor confidence.
Continued FDA review of multiple product candidates may indicate progress in drug development.
Negative
Lack of detailed financial metrics in the press release may raise concerns about transparency.
LEXINGTON, Mass.--(BUSINESS WIRE)--
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, March 9, 2023 to report financial results for the year ended December 31, 2022 and discuss recent corporate highlights.
The dial-in numbers are (833) 470-1428 for domestic callers and (404) 975-4839 for international callers. The access code is 202679. A live audio webcast of the conference call also will be accessible from the “Investors & Media” section of Aldeyra’s website at https://ir.aldeyra.com/.
After the live webcast, the event will remain archived on Aldeyra’s website for 90 days.
About Aldeyra
Aldeyra Therapeutics is a clinical-stage biotechnology company developing innovative therapies designed to treat immune-mediated diseases. Our approach is to discover and develop pharmaceuticals that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated diseases. Our pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease (under U.S. Food and Drug Administration New Drug Application review) and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of primary vitreoretinal lymphoma (under U.S. Food and Drug Administration New Drug Application review), proliferative vitreoretinopathy, and other rare sight-threatening retinal diseases. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.
